Journal of Cancer Research Reviews & Reports最新文献

Efficacy of Individualized Cancer Management 个性化癌症管理的功效

Journal of Cancer Research Reviews & Reports Pub Date : 2023-10-31 DOI: 10.47363/jcrr/2023(5)181

Kangla Tsung

{"title":"Efficacy of Individualized Cancer Management","authors":"Kangla Tsung","doi":"10.47363/jcrr/2023(5)181","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)181","url":null,"abstract":"Individualized cancer management is the opposite of the standardized care adapted for current clinical practice by the mainstream medicine. It is not a fancy concept but a logic and inevitable reality derived from the intrinsic characteristics of cancer and host antitumor response. The question is not whether it should be done but how it is done. One missing aspect of individualized management is how to measure its effectiveness. Unlike standardized management that compares therapy efficacy among different management plans by the statistical criteria on the entire groups of patients but not individual patient in the group, individualized management can measure the efficacy on individual patient. This is not only possible, but necessary. A true individualized cancer therapy is not only based on personal situation for each patient, but must also satisfy the criterion that the outcome of selected therapy is predictable for that patient, a feature that current standardized care does not have. Therapy selection based on the individualized assessment of the status of antitumor immunity in each patient is the essential part of individualized management. Thus, treating each patient according to the status of his antitumor immunity should be the most critical skills a physician needs to master when facing each individual cancer patient. In the past seven years, we have been exploring individualized management of cancer through recognizing and manipulating antitumor immunity in each patient. Our combined experiences indicate a significant benefit to patient survival with reduced costs even when such effort was not perfect in the past. With time and more learning, we see this practice becoming more and more practical in a clinical setting. When this individualized approach becomes guideline for cancer management, we will see a significant leap of clinical improvement on both patient survival and cancer cure rate","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139309348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating the Future: Nanotechnological Strategies for Tackling Hepatocellular Carcinoma 领航未来：应对肝细胞癌的纳米技术战略

Journal of Cancer Research Reviews & Reports Pub Date : 2023-10-31 DOI: 10.47363/jcrr/2023(5)180

Annu Kumari

{"title":"Navigating the Future: Nanotechnological Strategies for Tackling Hepatocellular Carcinoma","authors":"Annu Kumari","doi":"10.47363/jcrr/2023(5)180","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)180","url":null,"abstract":"Hepatocellular carcinoma (HCC), a widely prevalent form of liver malignancy, is a leading contributor to cancer-related mortality globally, despite advances in preventive and diagnostic technologies. It is closely associated with cirrhosis, with major contributions from hepatitis B and C infections and alcohol consumption. Early detection of HCC is crucial as it is often diagnosed at an asymptomatic stage. Radiological screenings and serological markers are effective methods of achieving early detection. Various surgical methods, including liver transplantation, and therapies such as radiofrequency lesioning and chemoembolization, are employed to treat this disease. However, due to limited donor availability and late diagnosis, treatment can be delayed. Tumour size, liver disease severity, and patient’s overall health are among the factors that influence the disease. Nanotechnology, a field that involves the precise manipulation of materials at the nanometer scale and the targeted delivery of therapeutic agents, presents a promising solution for HCC therapy. The utilization of nanoparticle-based therapies allows for the specific targeting of tumour-associated antigens, which enhances drug delivery and reduces drug-induced toxicity. Furthermore, nanomaterials such as carbon nanoparticles and biochemical sensors aid in the detection of oncological markers. Nanomedicine-based approaches possess the potential to revolutionize HCC therapy by improving drug delivery and targeting liver cancer stem cells. Specifically, targeted ligand-mediated therapy using saccharide or polysaccharide compounds, antibodies, peptides, and aptamers shows promise for liver-specific HCC treatment. Additionally, nanotherapy aimed at liver cancer stem cells (LCSCs) provides new possibilities to overcome the limitations of conventional treatments and improve patient outcomes. Ultimately, nanotechnology-based approaches hold great potential in enhancing the effectiveness of HCC therapy and offer new avenues for precision medicine in cancer treatment.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139308147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastatic Tumors of Unknown Primary (Muos) Definition, Frequency and General Considerations 原发不明的转移性肿瘤(Muos)的定义、频率和一般考虑

Journal of Cancer Research Reviews & Reports Pub Date : 2023-08-31 DOI: 10.47363/jcrr/2023(5)177

M. Hunis, A. Hunis

{"title":"Metastatic Tumors of Unknown Primary (Muos) Definition, Frequency and General Considerations","authors":"M. Hunis, A. Hunis","doi":"10.47363/jcrr/2023(5)177","DOIUrl":"https://doi.org/10.47363/jcrr/2023(5)177","url":null,"abstract":"Metastatic tumors of unknown primary (MUOs) present a diagnostic challenge due to the absence of an identifiable primary tumor site. The diagnostic approach for MUOs involves a comprehensive evaluation that includes clinical assessment, imaging studies, laboratory tests, and tissue sampling. Various imaging modalities, such as CT, MRI, PET scans, and ultrasound, are used to assess the extent of metastasis and identify potential primary tumor sites. Treatment options for MUOs include systemic therapies like chemotherapy, targeted therapy, immunotherapy, and hormone therapy, along with supportive care measures. Prognosis varies widely and is influenced by factors such as the extent of metastasis, tumor characteristics, treatment response, and patient factors [1]. Artificial intelligence (AI) has the potential to aid in diagnosis and management through image analysis, predictive modeling, pathology analysis, and risk assessment. The integration of AI requires careful validation and collaboration between healthcare professionals and AI experts. A multidisciplinary approach is crucial for optimal management of MUOs, and ongoing research aims to enhance diagnostic methods, treatment strategies, and prognostic models.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"75 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127164438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Study to Assess the Effect of Structured Teaching Programme on Knowledge of Patients with Acute Myeloid Leukaemia on Chemotherapy Schedule, Side Effects and its Management at a Tertiary Cancer Centre 某三级肿瘤中心急性髓系白血病患者化疗方案、副作用及治疗的结构化教学方案效果评估研究

Journal of Cancer Research Reviews & Reports Pub Date : 2023-06-30 DOI: 10.47363/jcrr/2023(5)172

Rashmi Methry

引用次数: 0

Public Policies on Cancer 有关癌症的公共政策

Journal of Cancer Research Reviews & Reports Pub Date : 2023-06-30 DOI: 10.47363/jcrr/2023(5)175

A. Hunis

引用次数: 0

A Rare Case of Malignant Phyllodes Tumor in a Young Female 年轻女性恶性叶状瘤1例

Journal of Cancer Research Reviews & Reports Pub Date : 2023-06-30 DOI: 10.47363/jcrr/2023(5)173

Quader Naseer

引用次数: 0

Unraveling the Cancer Metabolism: Fasting Reset, Ketogenic Diet? and Therapeutic Strategies 解开癌症代谢:禁食重置，生酮饮食?治疗策略

Journal of Cancer Research Reviews & Reports Pub Date : 2023-06-30 DOI: 10.47363/jcrr/2023(5)176

Eric B. Berg, G. Tenenbaum, Maurice Israel

引用次数: 0

Synchronous Serous Carcinoma of Ovary and Clear Cell Carcinoma of Kidney 卵巢同步浆液性癌和肾透明细胞癌

Journal of Cancer Research Reviews & Reports Pub Date : 2022-12-31 DOI: 10.47363/jcrr/2022(4)168

Namratha Sai Reddy B, N. Vaddeboina

引用次数: 0

Non-Small Cell Lung Cancer Metastases to Breast, Colon and Skin: A Case Report 非小细胞肺癌转移至乳房、结肠及皮肤1例报告

Journal of Cancer Research Reviews & Reports Pub Date : 2022-12-31 DOI: 10.47363/jcrr/2022(4)169

A. Mohammed, H. Bakhribah, R. Tulbah

引用次数: 0

The Impact of Sequencing Human Genome on the Psychosomatic Illnesses 人类基因组测序对心身疾病的影响

Journal of Cancer Research Reviews & Reports Pub Date : 2022-09-30 DOI: 10.47363/jcrr/2022(4)165

A. H. Khan

{"title":"The Impact of Sequencing Human Genome on the Psychosomatic Illnesses","authors":"A. H. Khan","doi":"10.47363/jcrr/2022(4)165","DOIUrl":"https://doi.org/10.47363/jcrr/2022(4)165","url":null,"abstract":"This abstract attempts to explore if psychosomatic illnesses are genetic in origin. The word psychosomatic comes from two roots: psycho meaning mind and somatic meaning body. The symptoms of psychosomatic illnesses are caused by emotional stress rather than an organic, physical source in the body. Our mind is outside of our brain and cannot be studied, but we can study its effect our body. To ensure if the psychosomatic illnesses have any association with our body and to identify the root cause of these illnesses in our body if any, we sequenced the human genome that is we read the entire book of our life. Our genome provides the total genetic information that make us humans. It carries the greatest catalog of human genes on planet Earth. Our genome consists of 46 volumes of encyclopedia called chromosomes which carry 24,000 chapters called genes. Of all genes in our genome, 16,000 are good genes, 6,000 bad (or mutated) genes responsible for causing six thousand different diseases and 2,000 pseudogenes which have lost their functions. Out of 6,000 variants, not a single mutated gene is linked to any symptom of psychosomatic disorders such as stress, hypertension, respiratory ailments, gastrointestinal disturbances, migraine, tension, headaches, pelvic pain, impotence, frigidity, dermatitis, ulcers. stress and anxiety. We examine the association of any of these psychosomatic symptoms with any of those six thousand mutated genes in our genome, we found no correlation with genetic diseases. We conclude that psychosomatic illnesses are not organic in nature and cannot be treated with organic molecules.","PeriodicalId":372137,"journal":{"name":"Journal of Cancer Research Reviews & Reports","volume":"172 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129521199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Journal of Cancer Research Reviews &amp; Reports最新文献

Journal of Cancer Research Reviews & Reports最新文献